Breaking News, Financial News

Financial Report: Gilead Sciences

Revenues up 97% driven by Sovaldi sales

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences   1Q Revenues: $5.0 billion (+97%) 1Q Earnings: $2.2 billion (+210%) Comments: Antiviral product sales were up 119% to $4.5 billion, driven by Hepatitis C drug Sovaldi, which launched in December 2013 and had $2.3 billion in sales. Stribild sales were up 134% to $215.3 million and Complera/Eviplera sales were up 69% to $250.7 million.Cardiovascular product sales increased to $234.5 million, up 9% primarily driven by Ranexa sales....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters